Experimental antiviral drug molnupiravir being developed by New Jersey drug manufacturer Merck with Ridgeback Bio shows a quick reduction of the infectious virus in a study among participants with early COVID-19.
Molnupiravir is being tested in a Phase 2/3 trial set to be completed in…